Predict your next investment

HEALTHCARE | Medical Devices & Equipment
antarespharma.com

See what CB Insights has to offer

Founded Year

1979

Stage

PIPE - V | IPO

Total Raised

$6.2M

Revenue

$0000 

About Antares Pharma

Antares Pharma is a Healthcare/Medical Devices & Equipment company based in Ewing, New Jersey. Antares Pharma's investors include Quogue Capital, Crestview Capital Funds, White Rock Capital Management, SDS Capital Partners, Midsummer Capital, Westpark Capital, AS Capital Partners, Sands Brothers Venture Capital, Drummer Capital Management, Atoll Asset Management, Alpha Capital Partners, Sandor Advisors, Paramount Capital Asset Management, Hauck & Aufh¤user Investment, Hudson Bay Capital Management, Heidtke & Company, Whalehaven Capital, Stonestreet, Nu Vision Holdings, Perceptive Advisors, Downsview Capital, Conus Partners, Professional Traders Management, North Sound Capital and Balyasny Asset Management.

Antares Pharma Headquarter Location

250 Phillips Boulevard Suite 290

Ewing, New Jersey, 08618,

United States

609-359-3020

Latest Antares Pharma News

Antares Pharma To Participate In The Piper Sandler 33rd Annual Virtual Healthcare Conference

Nov 22, 2021

Antares Pharma To Participate In The Piper Sandler 33rd Annual Virtual Healthcare Conference EWING, N.J. EWING, N.J., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. ( ATRS ) - Get Antares Pharma, Inc. Report (the "Company"), a specialty pharmaceutical company, today announced that Robert F. Apple, President and Chief Executive Officer, is scheduled to virtually present and host investor meetings at the Piper Sandler 33 rd Annual Virtual Healthcare Conference being held on November 29-December 2, 2021. A pre-recorded webcast of the fireside chat will be available under the "For Investors" section of the Antares Pharma website at www.antarespharma.com beginning on Monday, November 22 at 10am ET. About Antares Pharma Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug delivery auto injector technology. The Company has a portfolio of proprietary and partnered commercial products with several product candidates in various stages of development, as well as significant strategic alliances with industry leading pharmaceutical companies including Teva Pharmaceutical Industries, Ltd. (Teva), AMAG Pharmaceuticals (AMAG), Pfizer Inc. (Pfizer) and Idorsia Pharmaceuticals Ltd. (Idorsia). Antares Pharma's FDA-approved products include XYOSTED ® (testosterone enanthate) injection, OTREXUP ® (methotrexate) injection for subcutaneous use and Sumatriptan Injection USP, which is distributed by Teva. The Company also markets NOCDURNA ® (desmopressin acetate) in the U.S. and expects to commercially launch TLANDO ® (testosterone undecanoate) in the U.S. pending final FDA approval. SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to: the Company's ability to achieve the updated 2021 full-year revenue guidance; the uncertainty regarding the ongoing COVID-19 pandemic, including new strains of the virus, and the mitigation measures and other restrictions implemented in response to the same and the impact on demand for our products, new patients and prescriptions, future revenue, product supply, clinical trials, and our overall business, operating results and financial condition; commercial success of XYOSTED ® and future revenue from the same; market acceptance of Teva's generic epinephrine auto-injector product and future revenue from the same; future prescriptions and sales of OTREXUP ® ; successful commercialization of NOCDURNA ® in the U.S. and market acceptance and future revenue from the same; uncertainties regarding future FDA approval of TLANDO ® , market acceptance and future revenue from the same, whether Antares will exercise the option for LPCN 1111 ( TLANDO XR) and if exercised, future timing and success of the clinical development program for TLANDO XR and future FDA approval, market acceptance and revenue from the same; whether the FDA will withdraw marketing approval for AMAG Pharmaceuticals' Makena ® subcutaneous auto injector following the FDA letter seeking withdrawal, the outcome of the FDA hearing and whether Makena ® will be successful and future prescriptions, market acceptance and revenue from the same; Teva's ability to successfully commercialize VIBEX ® Sumatriptan Injection USP and the amount of revenue from the same; Teva's ability to successfully commercialize generic teriparatide in Europe, Canada and Israel and future revenue from the same, successful development including the timing and results of the Phase 3 trial of the drug device combination product for selatogrel with Idorsia Pharmaceuticals and FDA and global regulatory approvals and future revenue from the same; the timing and results of the clinical development program for ATRS-1902 adrenal crisis rescue auto-injector, future NDA submission and FDA approval of the same, and if approved, future market acceptance and revenue for the same; FDA approval of Teva's ANDAs for both generic Forteo ® and Byetta ® and future revenue from the same; the timing and results of the Company's or its partners' research projects or clinical trials of product candidates in development including the Company's urology assets in development as well as Pfizer's undisclosed development product; actions by the FDA or other regulatory agencies with respect to the Company's products or product candidates of its partners; continued growth in product, development, licensing and royalty revenue; the Company's ability to repay the debt obligation to Wells Fargo; the Company's ability to obtain financial and other resources for its research, development, clinical, and commercial activities and other statements regarding matters that are not historical facts, and involve predictions. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, achievements or prospects to be materially different from any future results, performance, achievements or prospects expressed in or implied by such forward-looking statements. In some cases you can identify forward-looking statements by terminology such as ''may'', ''will'', ''should'', ''would'', ''expect'', ''intend'', ''plan'', ''anticipate'', ''believe'', ''estimate'', ''predict'', ''potential'', ''seem'', ''seek'', ''future'', ''continue'', or ''appear'' or the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Additional information concerning these and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the "Risk Factors" section of the Company's Annual Report on Form 10-K, and in the Company's other periodic reports and filings with the Securities and Exchange Commission. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. All forward-looking statements are based on information currently available to the Company on the date hereof, and the Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this press release, except as required by law. Contact:Tram BuiVice President, Corporate Communications and Investor Relations609-359-3016 tbui@antarespharma.com By

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Antares Pharma Patents

Antares Pharma has filed 97 patents.

The 3 most popular patent topics include:

  • Drug delivery devices
  • Dosage forms
  • Medical equipment
patents chart

Application Date

Grant Date

Title

Related Topics

Status

10/29/2019

11/16/2021

Drug delivery devices, Medical equipment, Tires, Dosage forms, Flight training

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

10/29/2019

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

11/16/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Drug delivery devices, Medical equipment, Tires, Dosage forms, Flight training

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Antares Pharma Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Antares Pharma Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.